Antonio Rodriguez-Ariza

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/145596/publications.pdf

Version: 2024-02-01

70	2,420	172457	214800
papers	citations	29 h-index	47 g-index

70	70	70	3633
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial. British Journal of Cancer, 2022, 126, 874-880.	6.4	3
2	Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab. Cancers, 2022, 14, 3054.	3.7	1
3	Nitric oxide-targeted therapy inhibits stemness and increases the efficacy of tamoxifen in estrogen receptor-positive breast cancer cells. Laboratory Investigation, 2021, 101, 292-303.	3.7	7
4	Clinical Utility of microRNAs in Exhaled Breath Condensate as Biomarkers for Lung Cancer. Journal of Personalized Medicine, 2021, 11, 111.	2.5	13
5	The Combination of Neutrophilâ€“Lymphocyte Ratio and Plateletâ€“Lymphocyte Ratio with Liquid Biopsy Biomarkers Improves Prognosis Prediction in Metastatic Pancreatic Cancer. Cancers, 2021, 13, 1210.	3.7	18
6	Nitric oxide and tumor metabolic reprogramming. Biochemical Pharmacology, 2020, 176, 113769.	4.4	31
7	Circulating Cell-Free DNA-Based Liquid Biopsy Markers for the Non-Invasive Prognosis and Monitoring of Metastatic Pancreatic Cancer. Cancers, 2020, 12, 1754.	3.7	26
8	Association of Tumor Budding With Immune Evasion Pathways in Primary Colorectal Cancer and Patient-Derived Xenografts. Frontiers in Medicine, 2020, 7, 264.	2.6	10
9	SWATHâ€based proteomics reveals processes associated with immune evasion and metastasis in poor prognosis colorectal tumours. Journal of Cellular and Molecular Medicine, 2019, 23, 8219-8232.	3.6	15
10	Immunomodulatory roles of nitric oxide in cancer: tumor microenvironment says â€œNOâ€•to antitumor immune response. Translational Research, 2019, 210, 99-108.	5.0	39
11	Nitric Oxide Scavenging-Based Therapies for Targeting Colorectal Cancer. , 2019, , 159-171.		0
12	A role for endothelial nitric oxide synthase in intestinal stem cell proliferation and mesenchymal colorectal cancer. BMC Biology, 2018, 16, 3.	3.8	27
13	Exhaled breath condensate biomarkers for the early diagnosis of lung cancer using proteomics. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 313, L664-L676.	2.9	64
14	Ubiquinol Effects on Antiphospholipid Syndrome Prothrombotic Profile. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1923-1932.	2.4	60
15	S-Nitrosothiol Metabolism in Cancer and Therapeutic Implications. , 2017, , 211-222.		0
16	The addition of celecoxib improves the antitumor effect of cetuximab in colorectal cancer: role of EGFR-RAS-FOXM1-Î²-catenin signaling axis. Oncotarget, 2017, 8, 21754-21769.	1.8	20
17	KIR Genes and Their Ligands Predict the Response to Anti-EGFR Monoclonal Antibodies in Solid Tumors. Frontiers in Immunology, 2016, 7, 561.	4.8	11
18	â€˜Atherothrombosis-associated microRNAs in Antiphospholipid syndrome and Systemic Lupus Erythematosus patientsâ€™. Scientific Reports, 2016, 6, 31375.	3.3	44

#	Article	IF	Citations
19	Discovery of potential protein biomarkers of lung adenocarcinoma in bronchoalveolar lavage fluid by SWATH MS data-independent acquisition and targeted data extraction. Journal of Proteomics, 2016, 138, 106-114.	2.4	89
20	Altered S-nitrosothiol homeostasis provides a survival advantage to breast cancer cells in HER2 tumors and reduces their sensitivity to trastuzumab. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 601-610.	3.8	26
21	Genetic variants in the reninâ€“angiotensin system predict response to bevacizumab in cancer patients. European Journal of Clinical Investigation, 2015, 45, 1325-1332.	3.4	18
22	Simultaneous Inhibition of EGFR/VEGFR and Cyclooxygenase-2 Targets Stemness-Related Pathways in Colorectal Cancer Cells. PLoS ONE, 2015, 10, e0131363.	2.5	35
23	Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFÎ±. Arthritis Research and Therapy, 2015, 17, 49.	3.5	158
24	GCDCA down-regulates gene expression by increasing Sp1 binding to the NOS-3 promoter in an oxidative stress dependent manner. Biochemical Pharmacology, 2015, 96, 39-51.	4.4	14
25	Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus. Annals of the Rheumatic Diseases, 2015, 74, 1441-1449.	0.9	76
26	Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment. Annals of the Rheumatic Diseases, 2015, 74, 1450-1458.	0.9	49
27	CoCl2, a Mimic of Hypoxia, Induces Formation of Polyploid Giant Cells with Stem Characteristics in Colon Cancer. PLoS ONE, 2014, 9, e99143.	2.5	101
28	Anticyclic Citrullinated Protein Antibodies Are Implicated in the Development of Cardiovascular Disease in Rheumatoid Arthritis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2706-2716.	2.4	52
29	Proteomic approaches to evaluate protein sâ€nitrosylation in disease. Mass Spectrometry Reviews, 2014, 33, 7-20.	5.4	51
30	Cardiovascular Risk in Systemic Autoimmune Diseases: Epigenetic Mechanisms of Immune Regulatory Functions. Clinical and Developmental Immunology, 2012, 2012, 1-10.	3.3	38
31	Proteomics insights into deregulated proteinS-nitrosylation and disease. Expert Review of Proteomics, 2012, 9, 59-69.	3.0	8
32	Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q10 treatment. Blood, 2012, 119, 5859-5870.	1.4	82
33	Maintenance of S-nitrosothiol homeostasis plays an important role in growth suppression of estrogen receptor-positive breast tumors. Breast Cancer Research, 2012, 14, R153.	5.0	31
34	Nuclear Translocation of Î²-Catenin during Mesenchymal Stem Cells Differentiation into Hepatocytes Is Associated with a Tumoral Phenotype. PLoS ONE, 2012, 7, e34656.	2.5	45
35	Potential Use of Statins in the Treatment of Antiphospholipid Syndrome. Current Rheumatology Reports, 2012, 14, 87-94.	4.7	28
36	To Cardiovascular Disease and Beyond: New Therapeutic Perspectives of Statins in Autoimmune Diseases and Cancer. Current Drug Targets, 2012, 13, 829-841.	2.1	16

#	Article	IF	Citations
37	VEGF targeted therapy in acute myeloid leukemia. Critical Reviews in Oncology/Hematology, 2011, 80, 241-256.	4.4	30
38	Differential Bone Marrow Hematopoietic Stem Cells Mobilization in Hepatectomized Patients. Journal of Gastrointestinal Surgery, 2011, 15, 1459-1467.	1.7	6
39	Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. Annals of the Rheumatic Diseases, 2011, 70, 675-682.	0.9	82
40	AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia. Experimental Hematology, 2010, 38, 641-652.	0.4	6
41	Inhibition of nitric oxide synthesis during induced cholestasis ameliorates hepatocellular injury by facilitating S-nitrosothiol homeostasis. Laboratory Investigation, 2010, 90, 116-127.	3.7	23
42	977 INHIBITION OF NITRIC OXIDE SYNTHESIS DURING INDUCED CHOLESTASIS AMELIORATES HEPATOCELLULAR INJURY BY FACILITATING S-NITROSOTHIOL HOMEOSTASIS. Journal of Hepatology, 2010, 52, S377-S378.	3.7	0
43	Proteomic analysis for developing new biomarkers of hepatocellular carcinoma. World Journal of Hepatology, 2010, 2, 127.	2.0	13
44	Pharmacological impairment of s-nitrosoglutathione or thioredoxin reductases augments protein S-Nitrosation in human hepatocarcinoma cells. Anticancer Research, 2010, 30, 415-21.	1.1	19
45	Multivariate discriminant analysis distinguishes metal- from non metal-related biomarker responses in the clam Chamaelea gallina. Marine Pollution Bulletin, 2009, 58, 64-71.	5.0	13
46	Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia. Experimental Hematology, 2009, 37, 679-691.	0.4	13
47	Unraveling the S-nitrosoproteome: Tools and strategies. Proteomics, 2009, 9, 808-818.	2.2	34
48	Alteration of Sâ€nitrosothiol homeostasis and targets for protein Sâ€nitrosation in human hepatocytes. Proteomics, 2008, 8, 4709-4720.	2.2	26
49	Detection and Proteomic Identification of Sâ€Nitrosated Proteins in Human Hepatocytes. Methods in Enzymology, 2008, 440, 273-281.	1.0	15
50	S-nitrosation of proteins duringd-galactosamine-induced cell death in human hepatocytes. Free Radical Research, 2007, 41, 50-61.	3.3	9
51	Treatment of Refractory Cholestatic Pruritus With Molecular Adsorbent Recirculating System (MARS). Transplantation Proceedings, 2006, 38, 2511-2513.	0.6	38
52	Proteomic analysis of acute myeloid leukemia: Identification of potential early biomarkers and therapeutic targets. Proteomics, 2006, 6, S293-S299.	2.2	60
53	The differential effect of PGE1 on d-galactosamine-induced nitrosative stress and cell death in primary culture of human hepatocytes. Prostaglandins and Other Lipid Mediators, 2006, 79, 245-259.	1.9	12
54	Altered protein expression and protein nitration pattern during d-galactosamine-induced cell death in human hepatocytes: a proteomic analysis. Liver International, 2005, 25, 1259-1269.	3.9	19

#	Article	IF	Citations
55	Mutagenic activation of arylamines by subcellular fractions ofChamaelea gallinaclams exposed to environmental pollutants. Environmental and Molecular Mutagenesis, 2003, 41, 55-63.	2.2	3
56	Oxidative stress biomarkers in bivalves transplanted to the Guadalquivir estuary after AznalcÃ³llar spill. Environmental Toxicology and Chemistry, 2003, 22, 92-100.	4.3	36
57	Changes in protein expression profiles in bivalve molluscs (Chamaelea gallina) exposed to four model environmental pollutants. Proteomics, 2003, 3, 1535-1543.	2.2	150
58	Uptake and clearance of PCB congeners in Chamaelea gallina: response of oxidative stress biomarkers. Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2003, 134, 57-67.	2.6	13
59	Biochemical biomarkers of pollution in the clamChamaelea gallinafrom Southâ€Spanish littoral. Environmental Toxicology and Chemistry, 2002, 21, 542-549.	4.3	49
60	BIOCHEMICAL BIOMARKERS OF POLLUTION IN THE CLAM CHAMAELEA GALLINA FROM SOUTH-SPANISH LITTORAL. Environmental Toxicology and Chemistry, 2002, 21, 542.	4.3	6
61	Content of 8-oxodG in chromosomal DNA of Sparus aurata fish as biomarker of oxidative stress and environmental pollution. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 1999, 438, 97-107.	1.7	45
62	Rapid Induction of NF-ÎºB Binding during Liver Cell Isolation and Culture: Inhibition byL-NAMEIndicates a Role for Nitric Oxide Synthase. Biochemical and Biophysical Research Communications, 1999, 257, 145-148.	2.1	29
63	Formation of 8-oxoguanine in cellular DNA of Escherichia coli strains defective in different antioxidant defences. Mutagenesis, 1998, 13, 589-594.	2.6	24
64	The Levels of Ribonucleotide Reductase, Thioredoxin, Glutaredoxin 1, and GSH Are Balanced in Escherichia coli K12. Journal of Biological Chemistry, 1996, 271, 19099-19103.	3.4	60
65	Metabolic activation of carcinogenic aromatic amines by fish exposed to environmental pollutants. Environmental and Molecular Mutagenesis, 1995, 25, 50-57.	2.2	23
66	Promutagen activation by fish liver as a biomarker of littoral pollution. Environmental and Molecular Mutagenesis, 1994, 24, 116-123.	2.2	28
67	Rapid determination of glutathione status in fish liver using high-performance liquid chromatography and electrochemical detection. Biomedical Applications, 1994, 656, 311-318.	1.7	85
68	Biochemical and genetic indices of marine pollution in Spanish littoral. Science of the Total Environment, 1993, 134, 109-116.	8.0	36
69	Metal, mutagenicity, and biochemical studies on bivalve molluscs from Spanish coasts. Environmental and Molecular Mutagenesis, 1992, 19, 112-124.	2.2	78
70	Biochemical effects of environmental pollution in fishes from the Spanish South-Atlantic littoral. Biochemical Society Transactions, 1991, 19, 301S-301S.	3.4	31